Study finds, Safety and Efficacy of Dexamethasone Intracanal
A Study was conducted to evaluate the safety and efficacy of a dexamethasone sustained-release intracanalicular insert (DII) for control of inflammation and pain after pars plana vitrectomy (PPV) compared to standard topical steroid therapy. Control patients were matched by diagnosis and procedure performed.

The outcome was the proportion of patients with complete anterior chamber cell clearance (ACCC). Secondary outcomes included proportion developing intraocular pressure (IOP) more than 25 mmHg, change in mean optical coherence tomography central foveal thickness (OCT CFT), and proportion developing cystoid macular edema (CME) on qualitative analysis of OCT.

--The DII group had a statistically significant higher rate of complete ACCC compared to the topical steroid group.

--No eyes had IOP more than 25 mmHg in the DII, compared to 2 eyes in the topical steroid group.

--Overall, mean OCT CFT decreased in both groups; one patient had CME in the DII group, as compared to three in the topical steroid group.

Conclusively, the dexamethasone intracanalicular insert showed outstanding safety and efficacy in controlling postoperative inflammation following PPV.